Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

“This partnership creates an efficient and highly flexible logistics and distribution model for NRx. Cardinal Health’s expertise will enable ZYESAMI to quickly reach patients in the intensive care units, as limiting the time to treatment is crucial. This also allows NRx to continue focusing on answering requests from the FDA in support of our application for Emergency Use Authorization for ZYESAMI.” — Robert Besthof, Head of Operations and Chief Commercial Officer of NRx

https://pulse2.com/nrx-pharmaceuticals-nasdaq-nrxp-stock-over-16-increase-explanation/

“As the COVID-19 pandemic continues, so does the need for more innovative, effective and FDA-approved therapies for critically-ill patients with respiratory failure. Cardinal Health is pleased to ensure that COVID-19 patients get access to treatment in a timely and efficient manner.” — Marc DeLorenzo, Senior Vice President of Strategic Sourcing at Cardinal Health ——— Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.